Trends in Renal Research: Nephrology’s Shift to Focus and Precision

We trace how nephrology is shifting from historically slow, fragmented CKD megatrials to highly focused, biomarker driven programs built around patients and high prevalence regions. With expert insight from Caidya, we trace how nephrology is benefitting from a shift from historically slow, fragmented CKD megatrials to highly focused, biomarker driven programs built around patients, high prevalence regions, and an evolving global regulatory landscape. Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained by fragmented care, blunt endpoints, noisy signals, and overburdened patients, even as regulators and investors demand clearer…

Source: Clinical Trials Arena